Kelonia: CAR T-Cell Therapy for Multiple Myeloma
Eli Lilly has acquired Kelonia, a South Korean biotech firm developing next-generation CAR T-cell therapies for multiple myeloma, in a deal valued at approximately 10 trillion KRW ($7.2 billion USD), ... Read More